Identification and validation of prognostic genes associated with clear cell renal cell carcinoma: based on public whole transcriptome sequencing datasets - Scorecard - MDSpire
Advertisement
Identification and validation of prognostic genes associated with clear cell renal cell carcinoma: based on public whole transcriptome sequencing datasets
Clinical Scorecard: Discovery and validation of prognostic genes linked to clear cell renal cell carcinoma using public whole transcriptome sequencing data
At a Glance
Category
Detail
Condition
Clear cell renal cell carcinoma (ccRCC)
Key Mechanisms
Involvement of immune-related pathways and genetic alterations such as VHL mutation and 3p deletion.
Target Population
Patients diagnosed with clear cell renal cell carcinoma.
Care Setting
Oncology and clinical research settings utilizing transcriptome sequencing.
Key Highlights
Identification of eight prognostic genes associated with ccRCC.
Development of a risk stratification model based on gene expression.
Validation of gene expression through RT-qPCR in clinical samples.
Potential targeted drugs identified for specific prognostic genes.
Insights into the tumor immune microenvironment's role in ccRCC.
Guideline-Based Recommendations
Diagnosis
Utilize whole transcriptome sequencing for comprehensive gene expression profiling.
Management
Consider targeted therapies based on identified prognostic genes.
Monitoring & Follow-up
Regular assessment of gene expression levels in ccRCC patients.
Risks
20-30% of patients may experience metastatic recurrence postoperatively.
Patient & Prescribing Data
Patients with clear cell renal cell carcinoma undergoing treatment.
Amitriptyline hydrochloride and rituximab suggested as potential targeted therapies.
Clinical Best Practices
Integrate prognostic gene profiles into patient management strategies.
Utilize molecular docking studies to predict drug efficacy.
